NO994679L - Quinoline-2-carboxylic acid derivative and its use as excitatory amino acid antagonist - Google Patents

Quinoline-2-carboxylic acid derivative and its use as excitatory amino acid antagonist

Info

Publication number
NO994679L
NO994679L NO994679A NO994679A NO994679L NO 994679 L NO994679 L NO 994679L NO 994679 A NO994679 A NO 994679A NO 994679 A NO994679 A NO 994679A NO 994679 L NO994679 L NO 994679L
Authority
NO
Norway
Prior art keywords
quinoline
excitatory amino
carboxylic acid
amino acid
antagonist
Prior art date
Application number
NO994679A
Other languages
Norwegian (no)
Other versions
NO994679D0 (en
Inventor
Giuseppe Alvaro
Barbara Bertani
Romano Di Fabio
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of NO994679D0 publication Critical patent/NO994679D0/en
Publication of NO994679L publication Critical patent/NO994679L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

(+) enantiomer av E 4-(4-acetylaminofenylkarbamoylmetylen)-5,7-diklor- 1,2,3,4-tetrahydroquinolin 2-karboksylsyre og salt derav som er antagonist av eksitatoriske aminosyrer, fremgangsmåter for fremstilling derav, farmasøytiske blandinger inneholdende disse og anvendelse i legemidler er beskrevet.(+) Enantiomers of E 4- (4-acetylaminophenylcarbamoylmethylene) -5,7-dichloro-1,2,3,4-tetrahydroquinoline 2-carboxylic acid and salt thereof which are antagonist of excitatory amino acids, processes for their preparation, pharmaceutical compositions containing these and use in drugs are described.

NO994679A 1997-03-26 1999-09-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acid antagonist NO994679L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound
PCT/EP1998/001700 WO1998042673A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist

Publications (2)

Publication Number Publication Date
NO994679D0 NO994679D0 (en) 1999-09-24
NO994679L true NO994679L (en) 1999-11-24

Family

ID=10809909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994679A NO994679L (en) 1997-03-26 1999-09-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acid antagonist

Country Status (20)

Country Link
EP (1) EP0971896A1 (en)
JP (1) JP2001518901A (en)
KR (1) KR20010005567A (en)
CN (1) CN1257482A (en)
AP (1) AP9901659A0 (en)
AU (1) AU731394B2 (en)
BR (1) BR9808424A (en)
CA (1) CA2284710A1 (en)
EA (1) EA199900755A1 (en)
GB (1) GB9706294D0 (en)
HU (1) HUP0001661A3 (en)
ID (1) ID24306A (en)
IL (1) IL131919A0 (en)
IS (1) IS5186A (en)
NO (1) NO994679L (en)
NZ (1) NZ337793A (en)
PL (1) PL335865A1 (en)
TR (1) TR199902315T2 (en)
WO (1) WO1998042673A1 (en)
YU (1) YU47699A (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10132725A1 (en) 2001-07-05 2006-08-03 Grünenthal GmbH Substituted γ-lactone compounds
DE10137487A1 (en) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituted 5,6,6a, 11b-tetrahydro-7-oxa-6-aza-benzo [c] fluorene-6-carboxylic acid derivatives
DE10306202A1 (en) 2003-02-13 2004-08-26 Grünenthal GmbH 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist
JP4360891B2 (en) 2003-12-09 2009-11-11 アルパイン株式会社 Electronic device having broadcast receiving function and display method of electronic program guide in the device
KR101136183B1 (en) 2005-07-22 2012-04-17 모찌다 세이야쿠 가부시끼가이샤 Novel heterocyclidene acetamide derivative
RU2451014C2 (en) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Novel heterocyclidene acetamide derivative
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP7305560B2 (en) 2017-06-12 2023-07-10 グリテック， エルエルシー Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
TR199800531T1 (en) * 1995-09-29 1998-06-22 Glaxo Wellcome Spa Tetrahydroquinolines as NMDA antagonists.
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds

Also Published As

Publication number Publication date
GB9706294D0 (en) 1997-05-14
ID24306A (en) 2000-07-13
PL335865A1 (en) 2000-05-22
TR199902315T2 (en) 2000-05-22
AP9901659A0 (en) 1999-09-30
HUP0001661A3 (en) 2001-12-28
NZ337793A (en) 2001-02-23
JP2001518901A (en) 2001-10-16
WO1998042673A1 (en) 1998-10-01
IL131919A0 (en) 2001-03-19
AU7209498A (en) 1998-10-20
CN1257482A (en) 2000-06-21
AU731394B2 (en) 2001-03-29
EP0971896A1 (en) 2000-01-19
KR20010005567A (en) 2001-01-15
BR9808424A (en) 2000-05-23
EA199900755A1 (en) 2000-08-28
NO994679D0 (en) 1999-09-24
HUP0001661A2 (en) 2000-09-28
YU47699A (en) 2001-12-26
CA2284710A1 (en) 1998-10-01
IS5186A (en) 1999-09-17

Similar Documents

Publication Publication Date Title
TR199900049T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
TR200002015T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
NO20015226L (en) Tri-aryl acid derivatives such as PPAR receptor ligands, pharmaceutical composition comprising the same and use of the same for the preparation of drug.
ATE377597T1 (en) ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS
BR0116452A (en) Compound, pharmaceutical composition, use of a compound
HUP0004490A3 (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threoning kinase inhibitors and pharmaceutical compositions containing them
NO308798B1 (en) Protein kinase C inhibitors, use of same for the manufacture of pharmaceuticals and pharmaceutical formulation comprising the same
WO2003020698A3 (en) Protein tyrosine kinase inhibitors
BR0315547A (en) Quinoline derivatives as crth2 antagonists
HUP0002084A2 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases and pharmaceutical compositions containing them
IS2863B (en) Aripiprazole solution for oral administration
EE04275B1 (en) Quinoline derivatives, processes for their preparation, use and pharmaceutical compositions
IS1904B (en) Analogous Methods for Preparation of New (R) -5-Carbamoyl-8-Fluoro-3-N, N-Divided-Amino-3,4-Dihydro-2H-1-Benzopyranes
TR199801861T2 (en) Pharmaceutically useful compositions.
CA2327029A1 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
TR199900336T2 (en) Tetrahydroquinoline derivatives as EAA antagonists.
IL94278A0 (en) 2-saccharine derivatives,their preparation and pharmaceutical compositions containing them
NO994679L (en) Quinoline-2-carboxylic acid derivative and its use as excitatory amino acid antagonist
TR199800531T1 (en) Tetrahydroquinolines as NMDA antagonists.
TR200001102T2 (en) Substituted tetrahydropyrimidinene derivatives, their production and uses.
CY1106105T1 (en) MEGLUMINE SALT OF A SPECIFIC QUINOLINECARBOXYLIC ACID ACTIVE AT NMDA RECEPTORS
IS6402A (en) New branched substituted amino derivatives of 3-amino-1-phenyl-1H [1,2,4] triazole, methods for their preparation and pharmaceutical compositions containing them
ES2192789T3 (en) HYDRAZON-BENZAZULEN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND INTERMEDIATE COMPOUNDS.
BR9811954A (en) 3-aryl-succinamido-hydroxamic acids, processes for their production and pharmaceutical preparations containing these substances
YU26001A (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application